VIDEO: Stelara induces symptomatic, corticosteroid remission in patients with UC

ByKate Burba

In a video exclusive, Bruce Sands, MD, Icahn School of Medicine, reported Stelara demonstrated sustained remission in adults with moderate to severe ulcerative colitis in the phase 3 UNIFI study long-term extension period.

According to study results, every 12-week dosing of Stelara (ustekinumab, Janssen) or every 8-week dosing within an intention to treat population led to a symptomatic remission rate of 55.2% and a corticosteroid-free remission rate of 96.4% overall with sustained durability over time.

“The safety profile of this agent continues to be excellent,” Sands concluded. “Looking at the data out through week 156, when compared to the data of observed events and rates in patients who are on placebo ... we do not see excess rates of malignancies or serious infections, making this one of the safest agents that we use to treat UC.”

Published by:

Sources/Disclosures

Collapse

Source:

Sands B, et al. Abstract DOP83. Presented at: Congress of European Crohn’s and Colitis Organisation; July 8-10 (virtual meeting).
Sands B, et al. Abstract DOP86. Presented at: Congress of European Crohn’s and Colitis Organisation; July 8-10 (virtual meeting).

Disclosures: Sands reports consulting for AbbVie, Bacainn Therapeutics, Boehringer-Ingelheim, Boston Pharmaceuticals, Celltrion Healthcare, Genentech, Gilead Sciences, GlaxoSmithKline, InDex Pharmaceuticals, Inotrem, Janssen, Johnson & Johnson, Kallyope, Pfizer, Protagonist Therapeutics, Surrozen and Takeda Pharmaceuticals; serving on an advisory committee or review panel for Abivax, Arena Pharmaceuticals, Immunic, Ironwood Pharmaceuticals, Lilly, Prometheus Biosciences IBD and Target RWE.

Congress of European Crohn's and Colitis Organization

Read more

VIDEO: Stelara induces symptomatic, corticosteroid remission in patients with UC

Related Content